MedPath

amlapitta management with Abhayadi Vati

Phase 2
Completed
Conditions
Disease of stomach and duodenum, unspecified,
Registration Number
CTRI/2019/03/017993
Lead Sponsor
Institute for Post graduate Teaching and Research in Ayurveda Gujarat Ayurved University
Brief Summary

EtiopathologicaL study of kaphaja amlapitta and to find out effecacy of Abhayadi vati during this trial. Patients having sign and symptoms of Kaphaja Amlapitta were registered. Total 60 patients were registered in present study. All patients completed trial. No any patient was dropped out and found The trial drug Abhaydi vati had given 4 vati (500mg) after meal with honey twice in a day.that Abhayadi Vati had given a very signinificant results in subjective parameters of Kaphaja Amlapitta patients.

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
All
Target Recruitment
60
Inclusion Criteria

WILLING TO PARTICIPATE AGE BETWEEN 18 TO 60 YEAR PATIENTS HAVING SYMPTOMS OF KAPHAJA AMLAPITTA.

Exclusion Criteria

BELOW 18 YEARS AND ABOVE 60 YEARS OF AGE SUBJECT SUFFERING GIT DISORDERS OTHER THEN KAPHAJA AMLAPITTA 1 PEPTIC ULCER 2 DUODENAL ULCER 3 PANCREATIC AND HEPATIC DISEASE 4 INFLAMATORY BOWEL DISEASE 5 MALIGANCY OF GIT ANY SYSTEMIC DISEASE DM UNCONTROL HTN PATIENTS TAKINGS NASIDs NOT WILLING TO PATIENTS.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
assesment will be done after one month Relief in amlapitta symptomsRelief in amlapitta symptoms
Secondary Outcome Measures
NameTimeMethod
assess will be done after one month Relief in symptoms of kaphaja amlapittaRelief in symptoms of kaphaja amlapitta

Trial Locations

Locations (1)

Institute for post graduate teaching and research in ayurveda

🇮🇳

Jamnagar, GUJARAT, India

Institute for post graduate teaching and research in ayurveda
🇮🇳Jamnagar, GUJARAT, India
DR SANDEEP RAMAN
Principal investigator
8058244000
sandeepraman3@gmail.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.